TLR2 and chronic myelogenous leukemia, BCR-ABL1 positive: To determine the most effective maleimide to TLR2 peptide ratio, AML cell lines (HL60, U937 and Molm13) and CML cell line (K562) as control were treated with various liposomal formulations, including orid-liposome, orid-liposome-MAL, TLR2 pep-orid-liposome 1:1, and TLR2 pep-orid-liposome 5:1 over 24 or 48 h.